Residency · Residency · Medical Genetics Genomics
Newborn Screening: Principles, Methodology, and Follow-Up
Overview
Newborn screening (NBS) is a population-based public health program designed to identify infants with treatable conditions before clinical symptoms develop. It is based on the premise that early detection and intervention can prevent or ameliorate morbidity and mortality. Every state in the United States mandates NBS, though the specific conditions screened vary by state. The Recommended Uniform Screening Panel (RUSP) provides a national framework for standardization. The standard specimen is a dried blood spot (DBS) collected typically at 24-48 hours of life.
Principles of Newborn Screening
Wilson and Jungner Criteria (1968, Adapted)
The foundational principles hold that the condition should be an important health problem with a well-understood natural history and a recognizable latent or early symptomatic stage. A suitable and accepted screening test should exist, along with an accepted and effective treatment. Facilities for diagnosis and treatment should be accessible, and the cost of case-finding should be balanced against the cost of treating undetected cases. Case-finding should be an ongoing process.
Modern Adaptations
The original criteria focused on treatability, but the field is evolving to include conditions where early detection improves outcomes even without cure. Debate surrounds screening for conditions where treatment is emerging but not yet proven (such as Krabbe disease and MPS I), and tension exists between population-level benefit and individual-level harms (false positives, parental anxiety).
<image>Diagram illustrating the newborn screening workflow from birth through dried blood spot collection, laboratory analysis, result reporting, follow-up confirmatory testing, and initiation of treatment for affected infants</image>
Screening Methodologies
Tandem Mass Spectrometry (MS/MS)
Tandem mass spectrometry revolutionized NBS by enabling simultaneous detection of multiple metabolites from a single dried blood spot. It screens for amino acid disorders (PKU, MSUD, homocystinuria), organic acidemias (MMA, PA, IVA, GA-1), and fatty acid oxidation disorders (MCADD, VLCADD, LCHADD) by measuring acylcarnitine profiles and amino acid levels. High throughput allows hundreds of samples per day, though some conditions have overlapping metabolite profiles requiring second-tier testing.
Immunoassays
Immunoassay-based screening detects congenital hypothyroidism (TSH or T4), congenital adrenal hyperplasia (17-hydroxyprogesterone), cystic fibrosis (immunoreactive trypsinogen, elevated due to pancreatic damage in utero), biotinidase deficiency (biotinidase activity), and galactosemia (galactose-1-phosphate uridylyltransferase activity).
Molecular (DNA-Based) Testing
DNA-based NBS includes CFTR mutation panels as second-tier testing after elevated IRT for CF screening (IRT/DNA algorithm), SMN1 deletion analysis for spinal muscular atrophy (added to RUSP in 2018), and SCID screening via the TREC assay (T-cell receptor excision circles quantified by qPCR, where absent or low TRECs indicate severe combined immunodeficiency). Genomic sequencing as a supplemental or primary screening tool is an emerging application.
Other Methods
Additional screening methods include hemoglobin electrophoresis or HPLC for sickle cell disease and other hemoglobinopathies, enzyme activity assays for Pompe disease, MPS I, Krabbe disease, and X-ALD, pulse oximetry for critical congenital heart disease (point-of-care rather than DBS-based), and hearing screening via otoacoustic emissions or auditory brainstem response.
| Screening Method | Conditions Detected | Analyte/Marker | Key Limitations |
|---|---|---|---|
| Tandem mass spectrometry (MS/MS) | PKU, MSUD, organic acidemias, FAO disorders | Amino acids, acylcarnitines | Overlapping profiles; requires second-tier testing |
| Immunoassay | Congenital hypothyroidism, CAH, CF, biotinidase deficiency, galactosemia | TSH/T4, 17-OHP, IRT, enzyme activity | High false-positive rate for CAH in preterm infants |
| DNA-based molecular | SMA, CF (second-tier), SCID | SMN1 deletion, CFTR variants, TRECs | Cannot detect all variant types |
| Hemoglobin electrophoresis/HPLC | Sickle cell disease, thalassemia | Hemoglobin fractions | May miss beta-thalassemia trait at birth |
| Enzyme activity (DBS) | Pompe, MPS I, Krabbe, X-ALD | Lysosomal enzyme activity, C26:0 | Late-onset forms create counseling challenges |
| Pulse oximetry | Critical congenital heart disease | Oxygen saturation | Point-of-care; not DBS-based |
Recommended Uniform Screening Panel (RUSP)
Current Core Conditions (as of 2025)
The RUSP contains approximately 37 core conditions across categories including organic acid disorders (propionic acidemia, methylmalonic acidemia, isovaleric acidemia, glutaric acidemia type I, and others), fatty acid oxidation disorders (MCADD, VLCADD, LCHADD/TFP, carnitine uptake defect), amino acid disorders (PKU, MSUD, homocystinuria, citrullinemia, argininosuccinic aciduria, tyrosinemia type I), hemoglobin disorders (sickle cell disease variants), endocrine conditions (congenital hypothyroidism, congenital adrenal hyperplasia), and other conditions (CF, biotinidase deficiency, galactosemia, SCID, Pompe disease, MPS I, X-ALD, SMA, critical CHD, hearing loss). Approximately 26 secondary conditions are identified through screening for core conditions.
RUSP Nomination Process
Conditions are nominated to the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), which conducts evidence reviews considering clinical validity, clinical utility, feasibility, and public health impact. The Secretary of HHS makes final determinations. State adoption after RUSP addition varies in timing from months to years.
<image>Infographic of the RUSP showing core conditions organized by disease category (amino acid disorders, organic acidemias, FAO disorders, hemoglobinopathies, endocrine, lysosomal storage disorders, other) with the screening methodology used for each</image>
Follow-Up and Confirmatory Testing
Abnormal Screen Result Workflow
The workflow proceeds from notification (state NBS program or hospital notifies the primary care provider and/or specialist), through urgent recall (infant brought in for repeat specimen and/or immediate clinical evaluation), confirmatory testing (condition-specific diagnostic tests), clinical evaluation (assessment for symptoms, feeding history, growth), and treatment initiation (beginning immediately for confirmed conditions, some requiring treatment within days of life).
False Positives
False-positive rates vary by condition, typically ranging from 0.3-3% for most MS/MS conditions. The 17-OHP screen for CAH has a particularly high false-positive rate in premature and low birth weight infants. Consequences include parental anxiety, unnecessary follow-up testing, and cost. Second-tier testing (steroid profiling for CAH, DNA analysis for CF) reduces false-positive rates.
False Negatives
No screening test is 100% sensitive. Causes include specimen collected too early (before 24 hours), transfusion prior to hemoglobin screening, and milder forms of conditions with normal metabolites at birth. Late-onset or milder forms may not be detected on NBS. Clinical vigilance remains required even with a normal NBS result.
Time-Critical Conditions
Some conditions require intervention within days to prevent death or irreversible damage: galactosemia (stop lactose-containing feeds immediately), CAH salt-wasting form (hydrocortisone plus fludrocortisone before salt-wasting crisis in first 1-2 weeks), MSUD (metabolic crisis requiring leucine restriction), urea cycle defects (hyperammonemic crisis), and MCADD (prevent fasting with metabolic emergency protocol).
State Variation and Controversies
Screening Panel Variation
Despite the RUSP, states retain autonomy in determining their panels. Some states screen for additional conditions beyond the RUSP, creating inequity where an infant's screening depends on birth state. Advocacy groups push for universal RUSP adoption across all states.
Controversial Conditions
Krabbe disease, added in some states (New York was first), faces challenges including low PPV, uncertain benefit of early HSCT, and psychosocial burden of false positives and identification of late-onset forms. Duchenne muscular dystrophy is under consideration with creatine kinase as a potential biomarker. Lysosomal storage diseases (Pompe and MPS I are on RUSP) generate debate about screening for additional LSDs (Fabry, Gaucher, MPS II) due to identification of late-onset or attenuated forms.
Genomic Newborn Screening
Pilot programs (BabySeq, NC NEXUS, Guardian) are investigating the role of whole-genome or whole-exome sequencing in NBS. Potential benefits include expanding the range of detectable conditions, while concerns encompass VUS in asymptomatic newborns, parental consent, psychosocial impact, data storage and privacy, and cost.
Storage and Secondary Use of DBS
Residual DBS Specimens
After screening, residual DBS specimens are stored by state NBS programs for variable durations (some states store indefinitely, others for limited periods). Uses include quality assurance, public health research, forensic identification, and development of new screening tests.
Ethical and Legal Issues
Parental consent for storage and secondary use varies by state. Lawsuits have challenged unconsented use of DBS (in Texas and Minnesota, for example). Tension exists between public health benefit of biobanking and individual privacy rights, and some states now require explicit consent for research use.
<image>Map or comparison showing state-by-state variation in newborn screening panels in the United States, highlighting conditions screened beyond the RUSP and states that have not yet adopted all RUSP conditions</image>
Clinical Pearls
An abnormal NBS result is not a diagnosis -- confirmatory testing is always required before initiating treatment (except in emergencies like galactosemia where empiric dietary restriction begins pending confirmation). Premature infants frequently have false-positive results, particularly for CAH (17-OHP) and thyroid screening; repeat screening is recommended. A normal NBS does not rule out a metabolic condition; milder variants and late-onset forms may not be detected, and clinical suspicion should be maintained when symptoms arise. SMA screening detects homozygous SMN1 deletion only; carriers are not identified. SCID screening via TRECs also detects other causes of T-cell lymphopenia (22q11.2 deletion, trisomy 21, chylothorax) as "secondary" conditions. The IRT/DNA CF screening algorithm works as follows: elevated IRT triggers CFTR mutation analysis; one mutation identified means the infant needs a sweat test; two mutations are presumptive positive. Specimens collected before 24 hours of age may have higher false-positive rates for some analytes and should prompt repeat screening.
References
- Therrell BL, Padilla CD, Loeber JG, et al. "Current status of newborn screening worldwide: 2015." Seminars in Perinatology. 2015;39(3):171-187.
- Advisory Committee on Heritable Disorders in Newborns and Children. "Recommended Uniform Screening Panel." Health Resources and Services Administration (HRSA). Updated 2025.
- Kemper AR, Green NS, Calonge N, et al. "Decision-making process for conditions nominated to the recommended uniform screening panel." Genetics in Medicine. 2014;16(2):183-187.
- Wasserstein MP, Andriola M, Arnold G, et al. "Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State." Genetics in Medicine. 2016;18(12):1235-1243.
- Wilson JMG, Jungner G. "Principles and practice of screening for disease." WHO Public Health Papers No. 34. World Health Organization, 1968.
